Φορτώνει......
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation. In this study, we investigated axitinib activity against ponatinib-resis...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Hematol Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4523922/ https://ncbi.nlm.nih.gov/pubmed/26239229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0190-9 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|